Taiyen Biotech Co. Ltd. (1737) AI Stock Analysis

Taiyen Biotech Co. Ltd.

(TWSE:1737)

Select Model

Rating:67Neutral

Price Target:TWD 32.00▲(7.56% Upside)

Action:initiatedcoverage

Date:11/09/26

Taiyen Biotech scores in the upper-middle range, driven by a very conservative financial profile — effectively debt-free, equity-funded, with net margins and net income at six-year highs. An attractive 4.67% dividend yield and a modest 15.4x P/E add further support. These strengths are tempered by weak technicals, with the stock trading below all major moving averages on negative MACD and subdued RSI, and by fundamental limitations: low single-digit revenue growth, a modest 5.9% return on equity and a 2025 step-down in free cash flow due to heavy capital spending. Overall, a low-risk, income-friendly holding with limited near-term momentum or growth catalysts.

Positive Factors

Improving profitabilitySustained margin improvement indicates stronger earnings quality and better profitability from the existing business, rather than relying solely on revenue expansion. Higher operating and net margins can support reinvestment, strengthen resilience, and provide a durable base for earnings over the next several quarters.

Negative Factors

Limited revenue growthThe prolonged period of revenue pressure suggests that recent earnings improvement has been driven mainly by margins rather than expanding demand or volumes. Without stronger top-line growth, the company may have less operating leverage and a narrower path to sustaining profit expansion over time.

Taiyen Biotech Co. Ltd. (1737) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 5.95B
Dividend Yield: 4.71%
Average Volume (3M): 289.77K
Price to Earnings (P/E): 15.7
Beta (1Y): 0.06
Revenue Growth: -2.24%
EPS Growth: 12.99%
Country: TW
Employees: 479
Sector: General
Sector Strength: 55
Industry: Household & Personal Products

Taiyen Biotech Co. Ltd. Business Overview & Revenue Model

Company Description

Established in 1952 and headquartered in Tainan, Taiwan, Taiyen Biotech Co., Ltd. is a multifaceted enterprise engaged in the global production and distribution of salt-based goods. The company offers a wide-ranging portfolio that includes various sa...

Taiyen Biotech Co. Ltd. Financial Statement Overview

Summary

Financials are the company's strongest pillar. The balance sheet (88) is near debt-free, with a 3.3% debt-to-equity ratio and equity funding roughly 82% of assets, giving excellent resilience and financial flexibility. The income statement (71) shows a return to top-line growth in 2025 and a multi-year margin rebuild — gross margin near 40.6%, operating margin at 14.3% and net margin at 12.1%, with net income reaching a six-year high of NT$399.9 million. Cash flow (65) is the weak link: operating cash flow of NT$473.8 million still covers net income 1.19x, but fell from NT$660.1 million in 2024, and heavy capex cut free cash flow 38.5% to NT$173.6 million. Offsetting the strengths are muted growth (revenue still ~19% below 2021), a modest 5.9% return on equity and lumpy cash conversion.

Income Statement

71Positive

Balance Sheet

88Very Positive

Cash Flow

65Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.19B	3.31B	3.24B	3.41B	3.61B	4.10B
Gross Profit	1.25B	1.34B	1.32B	1.21B	1.28B	1.37B
EBITDA	676.56M	720.11M	657.96M	530.52M	640.00M	718.84M
Net Income	389.53M	399.87M	371.52M	300.39M	426.70M	393.23M
Balance Sheet
Total Assets	8.38B	8.26B	8.38B	8.32B	8.21B	8.47B
Cash, Cash Equivalents and Short-Term Investments	1.97B	1.75B	1.94B	1.84B	1.89B	2.08B
Total Debt	228.22M	223.20M	311.54M	317.19M	268.36M	506.55M
Total Liabilities	1.67B	1.45B	1.71B	1.77B	1.55B	1.95B
Stockholders Equity	6.71B	6.81B	6.66B	6.49B	6.52B	6.36B
Cash Flow
Free Cash Flow	278.67M	173.60M	352.51M	109.41M	334.09M	209.26M
Operating Cash Flow	583.78M	473.77M	660.12M	454.54M	580.69M	600.08M
Investing Cash Flow	-351.44M	-310.03M	-287.76M	-339.30M	-229.63M	-351.38M
Financing Cash Flow	-277.16M	-365.91M	-266.52M	-199.22M	-547.98M	-28.44M

Taiyen Biotech Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1737 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4205	73Outperform	TWD 6.27B	15.44	―	5.43%	0.29%	-7.81%
TW:1737	67Neutral	TWD 5.98B	15.74	―	4.71%	-2.24%	12.99%
TW:1734	64Neutral	TWD 6.07B	17.33	―	3.13%	2.44%	-3.96%
TW:1225	58Neutral	TWD 6.06B	126.50	―	0.50%	-4.19%	-84.08%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:1201	50Neutral	TWD 6.22B	26.90	―	1.72%	-4.41%	-18.82%
TW:1218	49Neutral	TWD 6.15B	-18.55	―	10.31%	-11.07%	-237.67%

* General Sector Average

Performance Comparison

TW:1737 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1737	Taiyen Biotech Co. Ltd.	29.75	-0.73	-2.39%
TW:1201	Wei Chuan Foods Corp.	12.20	-2.60	-17.57%
TW:1218	Taisun Enterprise Co., Ltd.	12.80	-4.38	-25.50%
TW:1225	Formosa Oilseed Processing Co., Ltd.	25.30	-5.75	-18.52%
TW:1734	Sinphar Pharmaceutical Co. Ltd.	30.15	1.76	6.19%
TW:4205	Chung Hwa Food Industrial Co., Ltd.	64.50	-16.90	-20.76%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Taiyen Biotech Co. Ltd. AI Stock Analysis